Related Experiment Video
Updated: Apr 28, 2026

11:07
Focal Laser Ablation of Prostate Cancer: An Office Procedure
Published on: March 30, 2021
9.8K
Histological difference between pulsed wave laser and continuous wave laser in endovenous laser ablation
Rei Kansaku1, Naoki Sakakibara2, Atsushi Amano3
1The Department of Cardiovascular Surgery, Edogawa Hospital, Tokyo, Japan The Department of Cardiovascular Surgery, Juntendo University, Tokyo, Japan kansaku-ths@umin.ac.jp.
Phlebology
|June 1, 2014
Summary
Pulsed wave laser ablation for saphenous veins is safer than continuous wave, avoiding vein perforation and ulcers. This minimally invasive treatment offers improved outcomes for chronic venous insufficiency.
Area of Science:
- Vascular Surgery
- Minimally Invasive Procedures
- Laser Technology
Background:
- Endovenous laser ablation (EVLA) is a common treatment for chronic venous insufficiency.
- Continuous wave (CW) lasers can cause adverse effects like vein perforation.
- Pulsed wave (PW) lasers may mitigate these risks by controlling energy delivery.
Purpose of the Study:
- To compare the safety and efficacy of pulsed wave (PW) versus continuous wave (CW) endovenous laser ablation (EVLA).
- To evaluate the incidence of vein perforation and other adverse effects associated with different EVLA modalities.
Main Methods:
- Comparison of CW and PW laser application in ex vivo venous models.
- Assessment of vein wall integrity and presence of clots after laser treatment.
- Evaluation of outcomes at different energy densities for 1470-nm CW laser.
Main Results:
- Continuous wave laser application resulted in fiber tip clots, unlike pulsed wave.
- CW laser use (980-nm and 1470-nm) led to significant rates of vein perforation and ulcers.
- 1320-nm pulsed wave laser ablation showed no instances of perforation or ulcers in treated venous specimens.
Conclusions:
- Pulsed wave endovenous laser ablation is a safer alternative to continuous wave, significantly reducing the risk of vein perforation.
- PW EVLA demonstrates a favorable safety profile compared to CW EVLA for treating saphenous vein insufficiency.

